Research Policy (in press) doi:10.1016/j.respol.2010.04.006
Albert Guangzhou Hu
Foreign applications for Chinese patents have been growing by over 30% a year. This paper explores two hypotheses in explaining the foreign patenting surge in China: market covering and competitive threat. With foreign companies more deeply engaged with the Chinese economy, returns from protecting their intellectual property [...]
Research Policy (in press) doi:10.1016/j.respol.2010.04.006
Albert Guangzhou Hu
Foreign applications for Chinese patents have been growing by over 30% a year. This paper explores two hypotheses in explaining the foreign patenting surge in China: market covering and competitive threat. With foreign companies more deeply engaged with the Chinese economy, returns from protecting their intellectual property in China have increased. As domestic Chinese firms’ ability to imitate foreign technology gains strength and competition between foreign firms intensifies in the Chinese market, such competitive threat creates an urgency for protecting intellectual property. Using a database that comprises China’s State Intellectual Property Office patents and the U.S. Patent and Trademark Office patents, I find strong support for the competitive threat hypothesis. The estimates imply that competition between foreign firms in China can account for 36% of the annual growth of foreign patenting in China.
India and Brazil launched a trade dispute against the European Union and the Netherlands in the World Trade Organisation on Wednesday over the seizure of generic medicines in transit.
The request for consultations, the first step in a formal World Trade Organization dispute, ratchets up the pressure in a row pitting the intellectual property rights [...]
India and Brazil launched a trade dispute against the European Union and the Netherlands in the World Trade Organisation on Wednesday over the seizure of generic medicines in transit.
The request for consultations, the first step in a formal World Trade Organization dispute, ratchets up the pressure in a row pitting the intellectual property rights of pharmaceutical corporations against access to affordable medicine for people in poor countries.
Source: Domain-B
This news covers an aspect of what we saw last year when Dutch authorities blocked generic medicine shipments destined for Nigeria and Brazil. The current trade negotiations between the EU and Central America try to strike a balance between access to medicine and enforcing the intellectual property regime. While both are needed, it remains to [...]
This news covers an aspect of what we saw last year when Dutch authorities blocked generic medicine shipments destined for Nigeria and Brazil. The current trade negotiations between the EU and Central America try to strike a balance between access to medicine and enforcing the intellectual property regime. While both are needed, it remains to be seen how this balance with be achieved.
Best regards, Joao
************
A new accord designed to bolster political and economic ties between the European Union and Central America could result in greater seizures of medicines whenever pharmaceutical companies allege that their patents have been infringed, public health advocates have warned. The EU is pushing for robust intellectual property clauses to be inserted in the “association agreement” under negotiation between the 27-country bloc and six Central American nations: Costa Rica, Guatemala, El Salvador, Honduras, Panama and Nicaragua.
Source: Intellectual Property Watch
A controversy has erupted in recent weeks in India, where consumer activists are arguing that intellectual property conferences sponsored by drugmakers, law firms and others are little more than gussied up opportunities to lobby India’s judges and policy makers. In their view, these IP summits, which are organized by the George Washington University Law School, [...]
A controversy has erupted in recent weeks in India, where consumer activists are arguing that intellectual property conferences sponsored by drugmakers, law firms and others are little more than gussied up opportunities to lobby India’s judges and policy makers. In their view, these IP summits, which are organized by the George Washington University Law School, are attempts to influence sitting judges on patent law enforcement issues that are pending in Indian courts.
“These meetings are being used as forums by companies to promote their intellectual property and to lobby for either law amendments or even to plead their cases currently pending before, for instance, the Indian Patent Office,” more than 20 consumer groups and non-governmental organizations wrote in a Feb. 26 letter to Shri Anand Sharma, India’s Minister of Commerce and Industry. They cite Novartis and Gilead as both sponsors and companies with pending patent disputes.
Read more, Source: Ed Silverman (Pharmalot)
The US biotechnology industry includes about 1,500 companies with combined annual revenue of about $70 billion. Major companies include Amgen, Biogen Idec, Genentech (owned by Switzerland-based Roche), Genzyme, Life Technologies, and Monsanto. Because many drugs are now developed using biotechnology, the biotechnology and pharmaceutical industries overlap considerably.
COMPETITIVE LANDSCAPE
Demand for biotechnology research in the [...]
The US biotechnology industry includes about 1,500 companies with combined annual revenue of about $70 billion. Major companies include Amgen, Biogen Idec, Genentech (owned by Switzerland-based Roche), Genzyme, Life Technologies, and Monsanto. Because many drugs are now developed using biotechnology, the biotechnology and pharmaceutical industries overlap considerably.
COMPETITIVE LANDSCAPE
Demand for biotechnology research in the fields of medicine, agriculture, food, and science is driven by insurers’ willingness to pay for new medical treatments, the global need to produce more food for a rapidly expanding population, and scientists’ desire to find solutions for complex scientific and medical issues. Funding for biotech research is often provided by venture capital funds hoping to cash in on new products. The profitability of individual companies depends on the discovery and effective marketing of new products. Because the market for potential products is so large, small biotechnology companies can co-exist successfully with large ones if they have expertise in a particular line of research. The industry is capital intensive: average annual revenue per worker is more than $350,000.
Biotech firms face stiff competition from pharmaceutical and other companies seeking to be first with a new product or discovery.
Full report available here
Thanks for your editorial calling on Liberals to vote in favour of Bill C-393, a private member’s bill to reform Canada’s Access to Medicines Regime. With this bill Canada has an opportunity to once again take a leadership position on humanitarian issues.
Critics say the bill is not compliant with current WTO rules, but international [...]
Thanks for your editorial calling on Liberals to vote in favour of Bill C-393, a private member’s bill to reform Canada’s Access to Medicines Regime. With this bill Canada has an opportunity to once again take a leadership position on humanitarian issues.
Critics say the bill is not compliant with current WTO rules, but international trade law experts have testified that it is WTO compliant.
Critics say providing for compulsory licenses allowing generic companies to produce patent-protected drugs for export to developing countries would constitute a disincentive to brand-name pharmaceutical research. Nonsense. The entire continent of Africa constitutes less than 2 per cent of global pharmaceutical sales. CAMR currently provides for royalties to be paid to the patent-holding company. Bill C-393 does not change this.
Read more here
Sign up for our mailing list:
Thanks for visiting!
- Access Asia Pacific Biotech Brazil China Counterfeit developing countries Drug Prices Emerging Markets Ethics Generics Health Insurance HIV/AIDS India Industrial Policy Innovation Intellectual Property Managed health care medicines Nanotechnology News pharmaceutical pharmaceutical policy Pharmacists Pharmacoeconomics Philippines Poverty public policy Quality R&D Regulatory Affairs Reimbursement Risk sharing Russia Singapore South Africa Supply Chain Taiwan Trade Vaccines
Archives
- October 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- November 2011
- September 2011
- April 2011
- February 2011
- January 2011
- December 2010
- November 2010
- September 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- October 2008
- July 2008
- October 2007
- November 2006
- October 2006
- November 2005
